JP2001517456A - アルツハイマー病の診断試験 - Google Patents
アルツハイマー病の診断試験Info
- Publication number
- JP2001517456A JP2001517456A JP2000512983A JP2000512983A JP2001517456A JP 2001517456 A JP2001517456 A JP 2001517456A JP 2000512983 A JP2000512983 A JP 2000512983A JP 2000512983 A JP2000512983 A JP 2000512983A JP 2001517456 A JP2001517456 A JP 2001517456A
- Authority
- JP
- Japan
- Prior art keywords
- ache
- glycosylation pattern
- isoform
- ratio
- wga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 113
- 238000002405 diagnostic procedure Methods 0.000 title description 7
- 108010022752 Acetylcholinesterase Proteins 0.000 claims abstract description 191
- 229940022698 acetylcholinesterase Drugs 0.000 claims abstract description 191
- 230000013595 glycosylation Effects 0.000 claims abstract description 50
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 50
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 claims abstract description 33
- 108010062580 Concanavalin A Proteins 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 27
- 210000001124 body fluid Anatomy 0.000 claims abstract description 10
- 239000010839 body fluid Substances 0.000 claims abstract description 7
- 102100033639 Acetylcholinesterase Human genes 0.000 claims description 186
- 102000001708 Protein Isoforms Human genes 0.000 claims description 69
- 108010029485 Protein Isoforms Proteins 0.000 claims description 69
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 41
- 239000002523 lectin Substances 0.000 claims description 21
- 108090001090 Lectins Proteins 0.000 claims description 19
- 102000004856 Lectins Human genes 0.000 claims description 19
- 102100032404 Cholinesterase Human genes 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 108090000322 Cholinesterases Proteins 0.000 claims description 8
- 229940048961 cholinesterase Drugs 0.000 claims description 7
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims description 6
- 238000000159 protein binding assay Methods 0.000 claims description 4
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 claims description 3
- 102000003914 Cholinesterases Human genes 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 5
- 210000005153 frontal cortex Anatomy 0.000 description 25
- 206010012289 Dementia Diseases 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 15
- 210000001638 cerebellum Anatomy 0.000 description 15
- 229920000936 Agarose Polymers 0.000 description 12
- 238000004062 sedimentation Methods 0.000 description 12
- 230000007423 decrease Effects 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 208000012902 Nervous system disease Diseases 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- 208000025966 Neurological disease Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 6
- 239000013504 Triton X-100 Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- IOIMDJXKIMCMIG-UHFFFAOYSA-N Diphosphoramide, N,N',N'',N'''-tetrakis(1-methylethyl)- Chemical compound CC(C)NP(=O)(NC(C)C)OP(=O)(NC(C)C)NC(C)C IOIMDJXKIMCMIG-UHFFFAOYSA-N 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000001652 frontal lobe Anatomy 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012134 supernatant fraction Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 2
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GFFIJCYHQYHUHB-UHFFFAOYSA-N 2-acetylsulfanylethyl(trimethyl)azanium Chemical compound CC(=O)SCC[N+](C)(C)C GFFIJCYHQYHUHB-UHFFFAOYSA-N 0.000 description 1
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 101100116283 Arabidopsis thaliana DD11 gene Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001640117 Callaeum Species 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- 235000010520 Canavalia ensiformis Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Chemical group CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241001634308 Dolichus Species 0.000 description 1
- 101100285518 Drosophila melanogaster how gene Proteins 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Chemical group C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 235000010666 Lens esculenta Nutrition 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 235000010730 Ulex europaeus Nutrition 0.000 description 1
- 102100031083 Uteroglobin Human genes 0.000 description 1
- 108090000203 Uteroglobin Proteins 0.000 description 1
- ZAEXMNKDGJNLTA-UHFFFAOYSA-N [4-[5-[4-[dimethyl(prop-2-enyl)azaniumyl]phenyl]-3-oxopentyl]phenyl]-dimethyl-prop-2-enylazanium Chemical compound C1=CC([N+](C)(CC=C)C)=CC=C1CCC(=O)CCC1=CC=C([N+](C)(C)CC=C)C=C1 ZAEXMNKDGJNLTA-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/827—Actinoplanes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO9432A AUPO943297A0 (en) | 1997-09-24 | 1997-09-24 | Diagnostic test for alzheimer's disease |
| AU9432 | 1997-09-24 | ||
| PCT/AU1998/000809 WO1999015695A1 (en) | 1997-09-24 | 1998-09-24 | Diagnostic test for alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001517456A true JP2001517456A (ja) | 2001-10-09 |
| JP2001517456A5 JP2001517456A5 (https=) | 2006-01-05 |
Family
ID=3803714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000512983A Pending JP2001517456A (ja) | 1997-09-24 | 1998-09-24 | アルツハイマー病の診断試験 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6461831B1 (https=) |
| EP (1) | EP1017845B1 (https=) |
| JP (1) | JP2001517456A (https=) |
| AT (1) | ATE323781T1 (https=) |
| AU (1) | AUPO943297A0 (https=) |
| BR (1) | BR9813015A (https=) |
| CA (1) | CA2304949A1 (https=) |
| DE (1) | DE69834263D1 (https=) |
| HU (1) | HUP0003684A3 (https=) |
| IL (1) | IL135211A0 (https=) |
| WO (1) | WO1999015695A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL130225A0 (en) | 1999-05-31 | 2000-06-01 | Yissum Res Dev Co | Novel uses of antibodies against ache and peptides thereof |
| US20020150878A1 (en) * | 2001-01-23 | 2002-10-17 | Small David Henry | Method for the diagnosis of Alzheimer's Disease and other prion related disorders |
| JP2006515927A (ja) * | 2002-12-20 | 2006-06-08 | モメンタ ファーマシューティカルズ インコーポレイテッド | 疾患を診断および監視するためのグリカンマーカー |
| GB2404734A (en) * | 2003-08-05 | 2005-02-09 | Secr Defence | A method of screening a sample for abnormally glycosylated and/or expressed proteins |
| US20060094064A1 (en) * | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| JP2007513337A (ja) * | 2003-11-19 | 2007-05-24 | サトリス， インコーポレイテッド | アルツハイマー病の診断方法、層化方法およびモニタリング方法 |
| US20050272643A1 (en) * | 2004-06-08 | 2005-12-08 | Windber Research Institute | Removal of serum albumin from human serum or plasma |
| US7851172B2 (en) | 2006-07-25 | 2010-12-14 | University Of Kentucky Research Foundation | Biomarkers of mild cognitive impairment and alzheimer's disease |
| US20100124756A1 (en) * | 2008-10-10 | 2010-05-20 | Sandip Ray | Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids |
| US20110237537A1 (en) * | 2009-05-29 | 2011-09-29 | Lombard Jay L | Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis |
| US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| US9493834B2 (en) | 2009-07-29 | 2016-11-15 | Pharnext | Method for detecting a panel of biomarkers |
| US20110202284A1 (en) * | 2010-02-10 | 2011-08-18 | Mcreynolds Cristopher | Novel groups of biomarkers for diagnosing alzheimer's disease |
| ES2395063B1 (es) * | 2011-03-04 | 2014-02-07 | Universidad Miguel Hernández De Elche | Método para determinar la enfermedad de Alzheimer mediante la detección de glicoproteínas portadoras del glicoepítopo HNK-1 |
| CA2877975C (en) | 2012-04-13 | 2021-09-21 | Oasis Diagnostics Corporation | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595883A (en) * | 1990-06-01 | 1997-01-21 | E. R. Squibb & Sons, Inc. | Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid |
| CA2048700A1 (en) | 1990-09-04 | 1992-03-05 | Dasakumar S. Navaratnam | Method for diagnosing senile dementia of the alzheimer type |
| US5200324A (en) * | 1990-09-04 | 1993-04-06 | E. R. Squibb & Sons, Inc. | Method of diagnosing senile dementia of the Alzheimer type |
-
1997
- 1997-09-24 AU AUPO9432A patent/AUPO943297A0/en not_active Abandoned
-
1998
- 1998-09-24 WO PCT/AU1998/000809 patent/WO1999015695A1/en not_active Ceased
- 1998-09-24 HU HU0003684A patent/HUP0003684A3/hu unknown
- 1998-09-24 AT AT98946146T patent/ATE323781T1/de not_active IP Right Cessation
- 1998-09-24 CA CA002304949A patent/CA2304949A1/en not_active Abandoned
- 1998-09-24 EP EP98946146A patent/EP1017845B1/en not_active Expired - Lifetime
- 1998-09-24 IL IL13521198A patent/IL135211A0/xx unknown
- 1998-09-24 DE DE69834263T patent/DE69834263D1/de not_active Expired - Lifetime
- 1998-09-24 US US09/509,203 patent/US6461831B1/en not_active Expired - Fee Related
- 1998-09-24 JP JP2000512983A patent/JP2001517456A/ja active Pending
- 1998-09-24 BR BR9813015-3A patent/BR9813015A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999015695A1 (en) | 1999-04-01 |
| ATE323781T1 (de) | 2006-05-15 |
| CA2304949A1 (en) | 1999-04-01 |
| EP1017845B1 (en) | 2006-04-19 |
| EP1017845A1 (en) | 2000-07-12 |
| HUP0003684A2 (hu) | 2001-02-28 |
| US6461831B1 (en) | 2002-10-08 |
| EP1017845A4 (en) | 2003-07-02 |
| DE69834263D1 (de) | 2006-05-24 |
| IL135211A0 (en) | 2001-05-20 |
| AUPO943297A0 (en) | 1997-10-16 |
| BR9813015A (pt) | 2000-08-15 |
| HUP0003684A3 (en) | 2003-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sáez‐Valero et al. | Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer’s disease | |
| Boza-Serrano et al. | Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease | |
| JP2001517456A (ja) | アルツハイマー病の診断試験 | |
| Dasouki et al. | Pompe disease: literature review and case series | |
| Paragh et al. | Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia | |
| Selcen et al. | Dok‐7 myasthenia: phenotypic and molecular genetic studies in 16 patients | |
| Sberna et al. | Acetylcholinesterase is increased in the brains of transgenic mice expressing the C‐terminal fragment (CT100) of the β‐amyloid protein precursor of Alzheimer's disease | |
| US5270165A (en) | Method of diagnosis of amyloidoses | |
| US20020022242A1 (en) | Diagnostic test for alzheimer's disease | |
| Lee et al. | Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy | |
| EP0564946A1 (en) | A diagnostic assay for alzheimer's disease based on the proteolysis of the amyloid precursor protein | |
| EP2813853B1 (en) | Use of an internal standard in a diagnostic method for Alzheimer's disease | |
| KR102144047B1 (ko) | 퇴행성 신경질환 진단용 조성물 | |
| US20090023145A1 (en) | Methods of diagnosing or prognosing Alzheimer's disease | |
| US5213962A (en) | Purification, detection and methods of use of protease Nexin-2 | |
| US5506097A (en) | Method for inhibiting β-protein enzymatic activity | |
| Silveyra et al. | Altered glycosylation of acetylcholinesterase in Creutzfeldt–Jakob disease | |
| EP0623146A1 (en) | COMPOUNDS AND METHODS FOR INHIBITING $g(b)-PROTEIN FUNCTION | |
| AU744215B2 (en) | Diagnostic test for Alzheimer's disease | |
| WO2003048384A2 (en) | Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms | |
| MXPA00002858A (en) | Diagnostic test for alzheimer's disease | |
| CZ20001053A3 (cs) | Diagnostický test na Alzheimerovu chorobu | |
| EP4071165A1 (en) | A new non-aggregative splicing isoform of human tau is decreased in alzheimer s disease | |
| Kizuka | Glycans and Alzheimer’s Disease | |
| PL190612B1 (pl) | Sposób diagnozowania choroby Alzheimera |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040728 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20040728 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040728 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050921 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080716 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081210 |